Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives
- PMID: 16362452
- DOI: 10.1007/s11095-005-9047-1
Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives
Abstract
Purpose: This study was conducted to assess the suitability of insulin analogs acylated by various cholic acid derivatives for use as basal insulin, and to test the most promising of these, LysB29(Nepsilon-lithocholyl-gamma-Glu) des(B30) human insulin (NN344) in pigs.
Methods: Circular dichroism spectroscopy and size-exclusion chromatography were used to explore the physicochemical properties of the analogs, and affinities for albumin and insulin receptors were determined. After subcutaneous injection in pigs, disappearance half-times were measured, and the plasma profile and glucose-lowering effect in a euglycemic clamp were assessed for NN344.
Results: NN344 showed glucose-lowering activity lasting more than 24 h. Glucose infusion rate was essentially constant from 5 to 19 h after injection. NN344 seemed to be a dodecamer in the presence of zinc ions and phenol. Without phenol, the apparent molecular mass was >5000 kDa. Formation of such a self-assembly at the site of s.c. injection and its subsequent slow decomposition might explain the long duration of action of NN344. A measurable affinity for albumin of the lithocholic acid ligand may also contribute to the prolonged action.
Conclusions: NN344 is a candidate for a neutral soluble basal insulin that might offer people with diabetes a prolonged duration, smooth, and predictable basal insulin supplement.
Similar articles
-
Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs.Diabetologia. 1996 Mar;39(3):281-8. doi: 10.1007/BF00418343. Diabetologia. 1996. PMID: 8721773
-
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Diabetes Obes Metab. 2007 May;9(3):290-9. doi: 10.1111/j.1463-1326.2006.00685.x. Diabetes Obes Metab. 2007. PMID: 17391154 Clinical Trial.
-
The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.Pharm Res. 2004 Aug;21(8):1498-504. doi: 10.1023/b:pham.0000036926.54824.37. Pharm Res. 2004. PMID: 15359587
-
Long-acting insulin analogs.Diabetes Care. 1999 Mar;22 Suppl 2:B109-13. Diabetes Care. 1999. PMID: 10097910 Review.
-
Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir.Int J Obes Relat Metab Disord. 2004 Sep;28 Suppl 2:S23-8. doi: 10.1038/sj.ijo.0802746. Int J Obes Relat Metab Disord. 2004. PMID: 15306834 Review.
Cited by
-
Glucose-responsive insulin by molecular and physical design.Nat Chem. 2017 Sep 22;9(10):937-943. doi: 10.1038/nchem.2857. Nat Chem. 2017. PMID: 28937662
-
Review: Glucose-sensitive insulin.Mol Metab. 2021 Apr;46:101107. doi: 10.1016/j.molmet.2020.101107. Epub 2020 Oct 31. Mol Metab. 2021. PMID: 33137487 Free PMC article. Review.
-
Improving long-term subcutaneous drug delivery by regulating material-bioenvironment interaction.Adv Drug Deliv Rev. 2018 Mar 1;127:20-34. doi: 10.1016/j.addr.2018.01.016. Epub 2018 Jan 31. Adv Drug Deliv Rev. 2018. PMID: 29391221 Free PMC article. Review.
-
Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.Medchemcomm. 2019 Jun 6;10(7):1068-1081. doi: 10.1039/c9md00018f. eCollection 2019 Jul 1. Medchemcomm. 2019. PMID: 31391879 Free PMC article. Review.
-
Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.Br J Pharmacol. 2014 Dec;171(23):5252-64. doi: 10.1111/bph.12843. Epub 2014 Sep 5. Br J Pharmacol. 2014. PMID: 25039358 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical